Dublin, March 14, 2019 (GLOBE NEWSWIRE) -- The "Global Pediatric Vaccine Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The pediatric vaccine market will register a CAGR of over 7% by 2023.

The prevalence of infectious diseases is high in the pediatric population, as the immune system of children is not fully developed. Therefore, infectious diseases are a leading cause of mortality in this population segment.

Factors such as rising population as well as environmental and a few genetic factors are contributing to the rapidly growing incidences of infectious diseases. For instance, increased exposure to environmental factors such as ultraviolet radiation is responsible for the suppression of cell-based immunity in children, which makes them susceptible to numerous infectious diseases.

Likewise, the rapid increase in birth rates is also a contributing factor to the rise in the number of infectious diseases. The increase in fertility rates is subsequently increasing the risk of maternally acquired infections such as HIV infection. All these factors are contributing to the increase in the prevalence of infectious diseases, which is further driving the market growth.

Strong late-stage pipeline and new drug approvals

The market contains a significant number of monotherapy- and combination therapy-based vaccines that are currently under the late stages of development and are expected to get approved during the forecast period.

These vaccines possess a strong therapeutic potential for the prevention of a large number of infectious diseases and allergies in children. The therapeutic potential of these vaccines can be demonstrated by the results of clinical trials.

Hurdles to optimal use of vaccines

Hurdles such as supply constraints, inadequate vaccine coverage, and lack of knowledge regarding the importance of immunization are restricting the optimal use of vaccines in both developing as well as developed countries. However, the lack of vaccination coverage is responsible for millions of deaths among the pediatric population.

Competitive Landscape

The pediatric vaccine market appears to be moderately concentrated with the presence of limited vendors. The increasing prevalence of infectious diseases in pediatric population will drive the market growth.

This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

• CSL Limited
• GlaxoSmithKline
  
• Merck & Co
  
• Pfizer
• Sanofi

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry

PART 07: MARKET SEGMENTATION BY PRODUCT

• Comparison by product
• Conjugate vaccines and others - Market size and forecast 2018-2023
• Live-attenuated vaccines - Market size and forecast 2018-2023
• Toxoid vaccines - Market size and forecast 2018-2023
• Inactivated vaccines - Market size and forecast 2018-2023
• Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

• Monovalent vaccines
• Multivalent vaccines

PART 10: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 14: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• CSL Limited
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/mjbbjx/global_pediatric?w=12